Results 41 to 50 of about 216,439 (378)

Conditional maximum likelihood timing recovery [PDF]

open access: yes, 1999
The conditional maximum likelihood (CML) principle, well known in the context of sensor array processing, is applied to the problem of timing recovery. A new self-noise free CML-based timing error detector is derived.
Riba Sagarra, Jaume   +1 more
core   +1 more source

Contracts in CML [PDF]

open access: yes, 2014
We describe the COMPASS Modelling Language (CML), which is used to model large-scale Systems of Systems and the contracts that bind them together. The language can be used to document the interfaces to constituent systems using formal, precise, and verifiable specifications including preconditions, postconditions, and invariants.
Jim Woodcock   +4 more
openaire   +2 more sources

Genotyping by sequencing for estimating relative abundances of diatom taxa in mock communities

open access: yesBMC Ecology and Evolution, 2023
Background Diatoms are present in all waters and are highly sensitive to pollution gradients. Therefore, they are ideal bioindicators for water quality assessment.
Ozan Çiftçi   +5 more
doaj   +1 more source

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

open access: yesLeukemia, 2018
Increasing evidence suggests that the immune system affects prognosis of chronic myeloid leukemia (CML), but the detailed immunological composition of the leukemia bone marrow (BM) microenvironment is unknown.
O. Brück   +12 more
semanticscholar   +1 more source

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]

open access: yes, 2018
The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core   +1 more source

CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.

open access: yesCancer Research, 2018
Chronic myeloid leukemia (CML) is a chronic disease resulting in myeloid cell expansion through expression of the BCR-ABL1 fusion transcript. Tyrosine kinase inhibitors (TKI) have significantly increased survival of patients with CML, and deep responders
Walid Warda   +16 more
semanticscholar   +1 more source

CML: the commonKADS conceptual modelling language [PDF]

open access: yes, 1994
We present a structured language for the specification of knowledge models according to the CommonKADS methodology. This language is called CML (Conceptual Modelling Language) and provides both a structured textual notation and a diagrammatic notation ...
Akkermans, J.M.   +5 more
core   +2 more sources

Evaluation of Imatinib adherence in chronic myeloid leukemia patients in Babylon Province, Iraq

open access: yesMedical Journal of Babylon, 2023
Background: Chronic myeloid leukemia is a clonal myeloproliferative neoplasm that results in proliferation, mainly of granulocytic components. Resulting from t(9;22) with fusion oncogen BCR-ABL1 which has uninhibited tyrosine kinase activity.
Athmar Kadhim Gatea   +2 more
doaj   +1 more source

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.

open access: yesBlood, 2017
Understanding leukemia heterogeneity is critical for the development of curative treatments as the failure to eliminate therapy-persistent leukemic stem cells (LSCs) may result in disease relapse.
Rebecca Warfvinge   +13 more
semanticscholar   +1 more source

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib [PDF]

open access: yes, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Hatziieremia, S.   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy